Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2005-05-24
2005-05-24
Stucker, Jeffrey (Department: 1648)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093100, C424S093300, C424S093600, C435S235100, C435S005000, C435S007100
Reexamination Certificate
active
06896882
ABSTRACT:
The present invention features therapeutic bacteriophage deficient in the lysin protein (“Lys minus” phage). Lys minus bacteriophage are incapable of facilitating efficient lysis of the bacterial host since the enzymatic activity of the lysin of the phage is needed for breaking down the peptidoglycan layer of the bacterial cell wall. Lys minus bacteriophage retain activity in invasion of its appropriate bacterial host, destruction of the bacterial genome, and replication, which are sufficient to inhibit bacterial growth and replication. Therefore, the therapeutic Lys minus phage stops the spread of infection by the bacterial pathogen without lysis of the bacterium. This approach is attractive as it also prevents the release of the phage progeny, thus reducing or eliminating the potential for generation of immune responses against the phage. The incapacitated bacterial pathogen is then removed by the normal defense systems such as phagocytes and macrophages.
REFERENCES:
patent: 4376110 (1983-03-01), David et al.
patent: 6056955 (2000-05-01), Fischetti et al.
patent: 6083684 (2000-07-01), Gasson
patent: 6130082 (2000-10-01), Majarian et al.
patent: 6395504 (2002-05-01), Trudil
Gründling et al. “Genetic and Biochemical Analysis of Dimer and Oligomer Interacitons of the λS Holin”, J. Bacteriol. Nov. 2000. 182(21):6082-6090.*
Devine et al. “EcoRI Cleavage Sites in the argECBHRegion of theEscherichia coli”, Chromosome J. Bacteriology, 1977. 129(2):1072-1077.*
Ackermann, “Tailed bacteriophages; the order caudovirales,”Adv Virus Res,51:135-201. (1998).
Arendt et al., Molecular Characterization of Lactorcoccal Bacteriophage Tuc2009 and Identification and Analysis of Genes Encoding Lysin, a Putative Holin, and Two Structural Proteins, Applied and Environment Microbiology, Jun. 1994, p. 1875-1883, vol. 60, No. 6.
Auad et al., “Physical mapping and partial genetic characterization of the Lactobacillus delbrueckii subsp. bulgaricus bacteriophage 1b539,”Arch Virol,144:1503-1512. (1999).
Boizet et al., “Cloning, expression and sequence analysis of an endolysin-encoding gene of Lactobacillus bulgaricus bacteriophage mv1.”Gene,94:61-67 (1990).
Botstein et al., “Strategies and Applications of in Vitro Mutagenesis,” Science 229, vol. 229, pg. 1193-1201, No. 4719 (1985).
Calandra et al., “Cellular streptolysin S-related hemolysins of group A Streptococcus C203S,”Infect Immun,12: 13-28. (1975).
Calandra et al., “Lysis and protoplast formation of group B streptococci by mutanolysin,”Infect Immun,28: 1033-1037 (1980).
Caldentey et al., The Lytic Enzyme of the Pseudommonas Phage Φ6, Purification and Biochemical Characterization, Biochimica et Biophysica Acta, 1159, 44-50 (1992).
Cattozzo et al., “Expression and Immunogenicity of V3Loop Epitopes of HIV-1, Isolates SC and WMJ2, Inserted in Salmonella Flagellin,” Journal Biotechnology 56 (1997) 191-203.
Chalfie et al., “Green Fluorescent Protein as a Marker for Gene Expression,” Science, vol. 263, 802-805 1994.
Chandry et al., “Analysis of the DNA sequence, gene expression, origin of replication and modular structure of theLactococcus lactislytic bacteriophage skl,”Mol Microbiol,26:49-64 (1997).
Cohen et al., “Simple procedure for production by group C streptococci of phage- associated lysin active against group A streptococci,”Appl Microbiol,29: 175-178 (1975).
Cole et al., “The EBV-hybridoma technique and its application to human lung cancer,” Monoclonal Antibodies And Cancer Therapy, Alan R. Liss, Inc., pp. 77-96 (1985).
Cote et al., “Generation of human monoclonal antibodies reactive with cellular antigens,” Proc. Natl. Acad. Sci. USA 80:2026-2030 (1983).
Coleman et al., “Cloning and expression inEscherichia coliandStaphylococcus aureusof the beta-lysin determinant fromStaphylococcus aureus:evidence that bacteriophage conversion of beta-lysin activity is caused by insertional inactivation of the beta-lysin determinant,” Microb Pathog, 1: 549-564 (1986).
Coleman et al.,Staphylococcus aureusbacteriophages mediating the simultaneous lysogenic conversion of beta-lysin,staphylokinase and enterotoxin A: molecular mechanism of triple conversion.J. Gen Microbiol,135.
Cooney et al., “Molecular cloning and genetic analysis of the determinant for gamma-lysin, a two-component toxin ofStaphylococcus aureus,” J Gen Microbiol,134:2179-2188 (1988).
Cormack, et al., “FACS-optimized mutants of the green fluorescent protein (GFP),” Gene, 173, 33-38 (1996).
de Ruyter et al., “Food-grade controlled lysis ofLactococcus lactisfor accelerated cheese ripening,”Nat Biotechnol,15:976-979 (1997).
Diaz et al., “The two-step lysis system of pneumococcal bacteriophage EJ-1 is functional in gram-negative bacteria: triggering of the major pneumococcal autolysin inEscherichia coli,” Mol Microbiol,19:667-681,
Dietrich et al., “Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicideListeria monocytogenes,” Nat. Biotechnol,16: 181-185 (1998).
Elias et al., “Staphylococcus aureushaemolysins: their use in strain typing,”Acta Microbiol Acad Sci Hung,27: 183-190 (1980).
Fischetti et al., “Purification and physical properties of group C streptococcal phage- associated lysine,”J. Exp. Med,133:1105-1117 (1971).
Gaeng et al., “Gene cloning and expression and secretion of listeria monocytogenes bacteriophage-lytic enzymes inlactococcus lactis,” Appl. Environ. Microbiol. 66, 2951 (2000).
Garcia et al., “Biochemical characterization of a murein hydrolase induced by bacteriophage Dp-1 inStreptococcus pneumoniae:comparative study between bacteriophage-associated lysin and the host amidase,”J.
Garcia et al., “Cloning, purification, and biochemical characterization of the pneumococcal bacteriophage Cp-1 lysin,”J Virol,61:2573-2580 (1987).
Garcia et al., “Mechanism of phage-induced lysis in pneumococci,” J Gen Microbiol, 129: 479-487. (1983).
Garrett, “Cell Lysis by induction of cloned lambda lysis genes,” J. et al. Mol. Gen. Genet. 182, 326 (1981).
Garvey et al., “Nucleotide sequence of bacillus phage Φ29 genes 14 and 15: homology of gene 15 with other phage lysozymes,” Nucleic Acids Res. 14, 10001 (1986).
Gindreau et al., “Molecular analysis of the region encoding the lytic system from Oenococcus oeni temperate bacteriophage phi 10MC,”FEMS Microbiol Lett,171:231-238 (1999).
Henikoff, “Undirectional digestion with exonuclease III creates targeted breakpoints for DNA sequencing,” Gene 28, 351 (1984).
Henrich et al., “Primary structure and functional analysis of the lysis genes ofLactobacillus gasseribacteriophage phi adh,”J. Bacteriol,177:723-732 (1995).
Higuchi et al., “A general method of in vitri preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions,” Nucleic Acids Res. 16, 7351 (1988).
Hill et al., Identification of a lysin associated with a bacteriophage (A25) virulent for group A streptococci,J Bacteriol,145: 696-703 (1981).
Inouye et al., “Bacteriophage T7 lysozyme is an n-acetylmuramyl-Lalanine amidase” Biol.Chem. 248, 7247 (1973).
Jain et al., “Use of lambda phage s and r gene products in an inducible lysis system for vibrio cholerae- and salmonella enterica serovar typhimurium-based DNA vaccine delivery systems,” Infect Immun. 68, 986 (2000).
Jerne, “Towards a network theory of the immune system,” Ann. Immunol. (Paris) 125c:373-389 (1974).
Jerne, N. K., et al., “Recurrent idiotopes and internal images,” EMBO 1:234 (1982).
Kaneko et al., “Complete nucleotide sequence and molecular characterization of the temperate staphylococcal bacteriophage phiPVL carrying Panton-Valentine le
Padmanabhan Sriram
Ramachandran Janakiraman
Sriram Bharathi
Bozicevic Field & Francis LLP
Francis Carol L.
Gangagen, Inc.
Stucker Jeffrey
LandOfFree
Lysin-deficient bacteriophages having reduced immunogenicity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lysin-deficient bacteriophages having reduced immunogenicity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lysin-deficient bacteriophages having reduced immunogenicity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3450000